Dashboard
1
High Debt Company with a Debt to Equity ratio (avg) at times
- Poor long term growth as Net Sales has grown by an annual rate of 0.75% and Operating profit at -12.05% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
- The company has been able to generate a Return on Capital Employed (avg) of 4.67% signifying low profitability per unit of total capital (equity and debt)
2
Negative results in Dec 24
3
Below par performance in long term as well as near term
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-31.91%
0%
-31.91%
6 Months
-38.95%
0%
-38.95%
1 Year
-44.86%
0%
-44.86%
2 Years
-28.8%
0%
-28.8%
3 Years
-15.4%
0%
-15.4%
4 Years
-62.62%
0%
-62.62%
5 Years
-57.19%
0%
-57.19%
Guerbet SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0.75%
EBIT Growth (5y)
-12.05%
EBIT to Interest (avg)
2.20
Debt to EBITDA (avg)
2.80
Net Debt to Equity (avg)
0.84
Sales to Capital Employed (avg)
1.04
Tax Ratio
30.40%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
4.67%
ROE (avg)
4.44%
Valuation key factors
Factor
Value
P/E Ratio
Industry P/E
Price to Book Value
0.47
EV to EBIT
NA
EV to EBITDA
EV to Capital Employed
0.72
EV to Sales
2.44
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
ROE (Latest)
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
Bullish
Bullish
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
841.10
785.70
7.05%
Operating Profit (PBDIT) excl Other Income
104.10
93.60
11.22%
Interest
20.50
10.60
93.40%
Exceptional Items
-2.00
1.90
-205.26%
Consolidate Net Profit
13.50
22.20
-39.19%
Operating Profit Margin (Excl OI)
50.90%
41.30%
0.96%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 7.05% vs 4.30% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -39.19% vs 154.01% in Dec 2023
About Guerbet SA 
Guerbet SA
Pharmaceuticals & Biotechnology
Guerbet SA is a France-based pharmaceutical group specialized in the manufacture and marketing of medical imaging contrast agents destined for diagnostic purposes. It produces medical imaging contrast products for x-ray imaging, magnetic resonance imaging (MRI), ultrasound imaging and for nuclear medicine. The contrast agents are used in the diagnosis of cardio-vascular, inflammatory and neuro-degenerative disorders. The Company’s portfolio of products comprises brands, such as Xenetix, Hexabrix, Optiray, Oxilan, Telebrix, Lipiodol, Dotarem, Endorem, Artirem, Lumirem, and Lipiodol, among others. Guerbet SA is also active in the fine chemicals industry through its Simafex subsidiary. The Company operates through its subsidiaries, including Simafex, Medex, SCI KALB, Guerbet LLC, Guerbet Asie Pacifique and Guerbet GmbH, among others.
Company Coordinates 
Company Details
15 rue des Vanesses, Zone Paris Nord II , VILLEPINTE None : 93420
Registrar Details






